These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 34597343)
21. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Dieterle MG; Rao K; Young VB Ann N Y Acad Sci; 2019 Jan; 1435(1):110-138. PubMed ID: 30238983 [TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Diversity of Preterm Neonates Is Associated With Couturier J; Lepage P; Jolivet S; Delannoy J; Mesa V; Ancel PY; Rozé JC; Butel MJ; Barbut F; Aires J Front Cell Infect Microbiol; 2022; 12():907323. PubMed ID: 35873148 [TBL] [Abstract][Full Text] [Related]
24. Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment. Pakpour S; Bhanvadia A; Zhu R; Amarnani A; Gibbons SM; Gurry T; Alm EJ; Martello LA Microbiome; 2017 Nov; 5(1):148. PubMed ID: 29132405 [TBL] [Abstract][Full Text] [Related]
25. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Murphy CK; O'Donnell MM; Hegarty JW; Schulz S; Hill C; Ross RP; Rea MC; Farquhar R; Chesnel L World J Gastrointest Pathophysiol; 2023 Aug; 14(4):71-85. PubMed ID: 37727283 [TBL] [Abstract][Full Text] [Related]
26. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Lomeli BK; Galbraith H; Schettler J; Saviolakis GA; El-Amin W; Osborn B; Ravel J; Hazleton K; Lozupone CA; Evans RJ; Bell SJ; Ochsner UA; Jarvis TC; Baqar S; Janjic N Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685472 [TBL] [Abstract][Full Text] [Related]
27. Aryl-alkyl-lysines: Novel agents for treatment of C. difficile infection. Ghosh C; AbdelKhalek A; Mohammad H; Seleem MN; Haldar J Sci Rep; 2020 Mar; 10(1):5624. PubMed ID: 32221399 [TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice. Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962 [TBL] [Abstract][Full Text] [Related]
29. In Vitro and In Vivo Anti- Islam MI; Seo H; Redwan A; Kim S; Lee S; Siddiquee M; Song HY J Microbiol Biotechnol; 2022 Jan; 32(1):46-55. PubMed ID: 34675143 [No Abstract] [Full Text] [Related]
30. Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units. Wang D; Dong D; Wang C; Cui Y; Jiang C; Ni Q; Su T; Wang G; Mao E; Peng Y Crit Care; 2020 Jul; 24(1):426. PubMed ID: 32660525 [TBL] [Abstract][Full Text] [Related]
31. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Mehta SR; Yen EF Transl Res; 2021 Apr; 230():197-207. PubMed ID: 33278650 [TBL] [Abstract][Full Text] [Related]
32. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459 [TBL] [Abstract][Full Text] [Related]
34. The microbial diversity following antibiotic treatment of Clostridioides difficile infection. Binyamin D; Nitzan O; Azrad M; Hamo Z; Koren O; Peretz A BMC Gastroenterol; 2021 Apr; 21(1):166. PubMed ID: 33849457 [TBL] [Abstract][Full Text] [Related]
35. Bacteriophage endolysins as a potential weapon to combat Mondal SI; Draper LA; Ross RP; Hill C Gut Microbes; 2020 Nov; 12(1):1813533. PubMed ID: 32985336 [No Abstract] [Full Text] [Related]
36. Fate of ingested Clostridium difficile spores in mice. Howerton A; Patra M; Abel-Santos E PLoS One; 2013; 8(8):e72620. PubMed ID: 24023628 [TBL] [Abstract][Full Text] [Related]
37. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection. van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573 [TBL] [Abstract][Full Text] [Related]
38. Effective inhibition of Clostridioides difficile by the novel peptide CM-A. Arthithanyaroj S; Chankhamhaengdecha S; Chaisri U; Aunpad R; Aroonnual A PLoS One; 2021; 16(9):e0257431. PubMed ID: 34516580 [TBL] [Abstract][Full Text] [Related]
39. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence. Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467 [TBL] [Abstract][Full Text] [Related]
40. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]